KP
UTHR icon

Keel Point’s United Therapeutics UTHR Stock Holding History

Keel Point’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-545
Closed -$266K – 564
2025
Q4 		$266K Buy
+545
New +$254K 0.02% 443

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Keel Point's UTHR Position: Q1 2026 in Review

Keel Point sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 545 shares — an estimated $266K sold.

Keel Point first reported a position in UTHR in Q4 2025 and held it in 1 quarter. The position peaked at $266K in Q4 2025. 854 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Keel Point reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Keel Point sold 545 United Therapeutics shares in Q1 2026, an estimated $266K.
  • Keel Point first reported a position in United Therapeutics in Q4 2025 and held it in 1 quarter.
  • Keel Point's United Therapeutics position peaked at $266K in Q4 2025.
  • 854 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Keel Point's 13F filing for Q1 2026, filed 1 Jun 2026.